Daily Newsletter

11 July 2024

Daily Newsletter

11 July 2024

Adona Medical raises funding to support clinical use of interatrial shunt

The Adona adjustable device is equipped with a shunt, which features a flow channel with an adaptable geometry.

Srivani Venna July 11 2024

Shifamed portfolio company Adona Medical has raised $33.5m in a Series C financing round for supporting the next stage of product development and initiating clinical use of its interatrial shunt and remote monitoring solution for heart failure patients.

The financing round was spearheaded by Cormorant Asset Management and TCP Health Ventures.

It also saw participation from the PA MedTech VC Fund II, Excelestar Ventures, Unorthodox Ventures, and AMED Ventures, along with other new and existing investors.

Cormorant Asset Management founder and managing member Bihua Chen said: “Despite advancements in heart failure therapies, challenges remain that limit patient applicability and physician adoption with first-generation devices.

“We are pleased to lead this round as we believe Adona's technology has the potential to disrupt the field and benefit the millions of patients suffering from heart failure.”

The Adona adjustable interatrial device is equipped with a shunt, which features a flow channel with an adaptable geometry.

This allows the shunt to be adjusted in size post-implantation using an induction catheter.

Furthermore, the implantable device includes integrated sensors. These are designed to capture pressure readings from the left as well as right atria several times a day, without requiring any interaction with the patient.

The daily readings collected by the device can provide physicians with a comprehensive understanding of a patient’s haemodynamic status. This, in turn, can enhance shunt therapy by enabling more informed medical management decisions.

The Adona Medical platform for heart failure management is currently an investigational device. It has not received approval for use in the US or any other country.

Heart failure is a condition that progressively affects approximately 6.5 million patients in the US and as many as 26 million patients worldwide.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close